Impact Biomedical (IBO) Total Current Liabilities (2022 - 2026)
Impact Biomedical's (IBO) quarterly Total Current Liabilities came in at $1.7 million in Q1 2026, down 83.08% YoY from $10.0 million in Q1 2025, and up 45.18% on a QoQ basis from $1.2 million in Q4 2025.
Impact Biomedical (IBO) Total Current Liabilities (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Total Current Liabilities data on file, last reported at $1.7 million in Q1 2026.
- Quarterly Total Current Liabilities fell 83.08% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 83.08% YoY) and the FY2025 annual result came in at $1.2 million, down 88.12% from the prior year.
- Total Current Liabilities rose to $1.7 million in Q1 2026, from $1.2 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $23.8 million in Q3 2025 to a low of $1.1 million in Q3 2024.
- A 5-year average of $11.3 million and a median of $12.1 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities tumbled 90.72% — and 2025, when it jumped 1990.77%.
- Tracing IBO's Total Current Liabilities over 5 years: stood at $10.6 million in 2022, then advanced by 24.01% to $13.1 million in 2023, then retreated by 25.51% to $9.8 million in 2024, then plunged by 88.12% to $1.2 million in 2025, then jumped by 45.18% to $1.7 million in 2026.
- The last three Total Current Liabilities figures came in at $1.7 million (Q1 2026), $1.2 million (Q4 2025), and $23.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | 2.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.05 Mn |
| Mar 31, 2026 | 1.69 Mn |
| Dec 31, 2025 | 1.16 Mn |
| Sep 30, 2025 | 23.79 Mn |
| Jun 30, 2025 | 23.17 Mn |
| Mar 31, 2025 | 9.97 Mn |
| Dec 31, 2024 | 9.79 Mn |
| Sep 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 14.50 Mn |
| Mar 31, 2024 | 13.86 Mn |
| Dec 31, 2023 | 13.14 Mn |
| Sep 30, 2023 | 12.27 Mn |
| Jun 30, 2023 | 12.06 Mn |
| Dec 31, 2022 | 10.59 Mn |